Segment Information (Tables)

9 Months Ended

Sep. 30, 2017

Segment Information

Schedule of net product sales, cost of product sales and gross profit for each commercial product

Net product sales, cost of product sales and gross profit for each of our commercial products were as follows (in millions):

	Three Months Ended September 30,
2017	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
Net product sales	$	187.3	$	88.9	$	99.8	$	52.5	$	17.0	$	445.5
Cost of product sales	4.0		2.2		5.6		3.9		3.8		19.5
Gross profit	$	183.3	$	86.7	$	94.2	$	48.6	$	13.2	$	426.0
2016
Net product sales	$	152.4	$	101.8	$	96.0	$	40.7	$	17.3	$	408.2
Cost of product sales	3.7		5.8		5.5		5.2		3.4		23.6
Gross profit	$	148.7	$	96.0	$	90.5	$	35.5	$	13.9	$	384.6

	Nine Months Ended September 30,
2017	Remodulin		Tyvaso		Adcirca		Orenitram		Unituxin		Total
Net product sales	$	490.8	$	280.5	$	300.4	$	137.8	$	51.1	$	1,260.6
Cost of product sales	9.9		7.9		16.9		10.7		7.3		52.7
Gross profit	$	480.9	$	272.6	$	283.5	$	127.1	$	43.8	$	1,207.9
2016
Net product sales	$	451.1	$	311.0	$	259.5	$	118.9	$	49.3	$	1,189.8
Cost of product sales	4.3		12.9		15.0		7.9		4.2		44.3
Gross profit	$	446.8	$	298.1	$	244.5	$	111.0	$	45.1	$	1,145.5